Welcome to our dedicated page for XOMA Royalty Corporation news (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation stock.
XOMA Royalty Corporation (Nasdaq: XOMA) is a biotechnology royalty aggregator that regularly reports on transactions, partner developments, and portfolio evolution. News about XOMA Royalty often centers on its acquisition of royalty and milestone interests in therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies, as well as on corporate events that affect its capital structure and governance.
Recent announcements highlight XOMA Royalty’s completion of acquisitions of companies such as HilleVax, LAVA Therapeutics, Mural Oncology, and Turnstone Biologics, which add partnered programs and associated economic interests to its portfolio. The company also issues updates on strategic royalty-sharing transactions, including amendments to its collaboration with Takeda related to mezagitamab and exposure to a basket of development-stage assets in Takeda’s externalized assets portfolio.
Investors following XOMA Royalty news will see regular disclosures on quarterly and year-to-date financial results, including royalty and milestone receipts from commercial assets like VABYSMO, OJEMDA, MIPLYFFA, XACIATO, IXINITY, and DSUVIA. The company’s releases also summarize key clinical and regulatory milestones reported by its partners, since these events can influence the timing and magnitude of potential royalty and milestone payments.
Additional news items cover preferred stock dividends on the company’s Series A and Series B Cumulative Perpetual Preferred Stock, at-the-market offerings of common and preferred securities, and leadership changes such as transitions in the Chief Financial Officer role. For investors and observers, the XOMA Royalty news feed provides a consolidated view of business development activity, partner pipeline progress, financing decisions, and governance updates that shape the company’s royalty and milestone portfolio over time.
XOMA Corporation (Nasdaq: XOMA) announced cash dividends for its Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A stock will receive $0.53906 per share, while those with the 8.375% Series B stock will receive $0.52344 per depositary share. These dividends are payable on approximately October 17, 2022, to shareholders on record by October 3, 2022. XOMA operates as a biotechnology royalty aggregator, having acquired rights to over 70 assets linked to therapeutic candidates, providing funding to biotechs for their R&D initiatives.
XOMA Corporation will have its CEO, Jim Neal, present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022, at 10:00 AM ET. The conference aims to highlight XOMA's role as a biotechnology royalty aggregator, helping companies enhance human health by acquiring future economic rights linked to pre-commercial therapeutic candidates. A live stream of the presentation will be accessible here and on XOMA's website. A replay will be available for 90 days post-event.
XOMA Corporation reported its second quarter 2022 financial results, achieving total revenues of $1.0 million, up from $0.9 million in Q2 2021. The net loss widened to $4.7 million compared to $2.2 million in the prior year. Cash at the end of June stood at $83.2 million, with no debt, which management believes will sustain operations for several years. The acquisition of Checkmate Pharmaceuticals resulted in a $2.5 million payment to XOMA, while Rezolute and Day One plan to advance to Phase 3 clinical trials, signaling positive progress in their pipelines.
XOMA Corporation (Nasdaq: XOMA) has announced cash dividends for holders of its Series A and B Cumulative Preferred Stock. Shareholders of the 8.625% Series A stock will receive $0.53906 per share, while holders of the 8.375% Series B stock will receive $0.52344 per depositary share. The dividends are scheduled for payment on July 15, 2022, to shareholders on record by July 1, 2022. XOMA plays a significant role as a biotechnology royalty aggregator, managing over 70 assets related to therapeutic candidates, providing crucial funding for biotech advancement.
XOMA Corporation, a biotechnology royalty aggregator, announced that its Chairman and CEO, Jim Neal, will present at the H.C. Wainwright Global Investment Conference on May 25, 2022, at 10:00 AM ET. The presentation will be accessible online and archived for 90 days post-event. XOMA focuses on acquiring potential future earnings from pre-commercial therapeutic candidates, providing non-dilutive funding to sellers. The company's portfolio includes over 70 assets associated with drug products in development, underscoring its impact on improving human health.
XOMA Corporation (Nasdaq: XOMA) reported a strong financial performance for Q1 2022, with total revenues of $3.1 million, up from $0.4 million in Q1 2021. This increase was propelled by a $2 million milestone from Rezolute for the RZ358 study. The company concluded Q1 2022 with cash and restricted cash totaling $88.6 million and no debt. Notably, XOMA recognized a net loss of $2.3 million, a significant improvement compared to a $7.4 million loss in the prior year. The firm remains optimistic about its financial stability and future operations.
XOMA Corporation (Nasdaq: XOMA) announced cash dividends for holders of its Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A Cumulative Preferred Stock (Nasdaq: XOMAP) will receive $0.53906 per share, while holders of depositary shares representing 1/1000 of the Series B Cumulative Preferred Stock (Nasdaq: XOMAO) will receive $0.52344 per share. The dividends will be paid on or about April 15, 2022, to shareholders on record as of April 1, 2022.
On March 10, 2022, XOMA Corporation (Nasdaq: XOMA) announced that Chairman and CEO Jim Neal will present at Oppenheimer’s 32nd Annual Healthcare Conference on March 17, 2022, at 12:40 PM ET. This virtual event can be accessed through a direct link or via the investor relations section of XOMA's website, where a replay will be available for 90 days. XOMA specializes in acquiring future royalties from pre-commercial therapeutic candidates, providing non-dilutive funding to biotech companies. The company has an extensive portfolio with over 70 assets.
XOMA Corporation (Nasdaq: XOMA) reported a strong financial performance in 2021, earning $36.2 million in milestone payments and achieving positive operating cash flow for the second consecutive year. Key highlights include a $35 million milestone from its Anti-TGFβ Antibody License Agreement with Novartis. Total revenues reached $38.2 million in 2021, up from $29.4 million in 2020. The company ended the year with $95.4 million in cash and no debt. Significant advances include commercialization approval for a bispecific antibody and progress in multiple drug candidates. CEO succession planning is underway.
XOMA Corporation, a biotechnology royalty aggregator, announced that its Chairman and CEO, Jim Neal, will participate in a fireside chat at the 42nd Annual Cowen Health Care Conference. The event is scheduled for March 7, 2022, at 1:30 PM ET. Investors can access the presentation live or via a replay on the company's website for 90 days post-event. XOMA plays a crucial role in advancing human health by acquiring potential future economics from pre-commercial therapeutic candidates, boasting a portfolio of over 70 assets.